{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:17:26Z","timestamp":1760141846043,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.soncn.2012.05.004","type":"journal-article","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T04:39:44Z","timestamp":1343450384000},"page":"154-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Urothelial Cancers: Ureter, Renal Pelvis, and Bladder"],"prefix":"10.1016","volume":"28","author":[{"given":"Allison","family":"Tyler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soncn.2012.05.004_bib1","unstructured":"American Cancer Society. Bladder cancer. Atlanta, GA; American Cancer Society. Available at: http:\/\/www.cancer.org\/Cancer\/BladderCancer\/DetailedGuide\/bladder-cancer-what-is-bladder-cancer (accessed March 3, 2012)."},{"key":"10.1016\/j.soncn.2012.05.004_bib2","series-title":"Textbook of bladder cancer","first-page":"237","article-title":"Etiology and management of urothelial tumors of the renal pelvis and ureter","author":"Lima","year":"2006"},{"key":"10.1016\/j.soncn.2012.05.004_bib3","unstructured":"American Cancer Society. Bladder cancer statistics. Atlanta, GA; American Cancer Society. Available at: www.cancer.org (accessed March 3, 2012)."},{"year":"2010","series-title":"The Cleveland Clinic guide to bladder cancer","author":"Raghavan","key":"10.1016\/j.soncn.2012.05.004_bib4"},{"key":"10.1016\/j.soncn.2012.05.004_bib5","series-title":"Textbook of bladder cancer","first-page":"207","article-title":"Cytology and DNA ploidy","author":"White","year":"2006"},{"key":"10.1016\/j.soncn.2012.05.004_bib6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/CCO.0b013e3283378c6b","article-title":"Bladder cancer","volume":"22","author":"Morgan","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.soncn.2012.05.004_bib7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0022-5347(17)69924-5","article-title":"Infiltrating carcinoma of the bladder. Relation of depth penetration of the bladder wall to incidence of local extension and metastases","volume":"55","author":"Jewett","year":"1946","journal-title":"J Urol"},{"first-page":"497","year":"2010","series-title":"American Joint Committee on Cancer. AJCC Cancer Staging Handbook","key":"10.1016\/j.soncn.2012.05.004_bib8"},{"key":"10.1016\/j.soncn.2012.05.004_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.urology.2011.03.032","article-title":"Effect of age on transitional cell carcinoma of the upper urinary tract: presentation, treatment, and outcomes","volume":"78","author":"Yap","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.soncn.2012.05.004_bib10","unstructured":"National Cancer Institute. Transitional cell cancer of the renal pelvis and ureter treatment. Bethesda, MD; National Cancer Institute. Available at: http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/transitionalcell\/HealthProfessional (accessed October 2, 2011)."},{"key":"10.1016\/j.soncn.2012.05.004_bib11","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.eururo.2009.07.002","article-title":"Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy","volume":"57","author":"Raman","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib12","series-title":"Campbell's urology","first-page":"2383","article-title":"Urothelial tumours of the renal pelvis and ureter","author":"Messing","year":"2002"},{"key":"10.1016\/j.soncn.2012.05.004_bib13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0022-5347(17)67069-1","article-title":"Radiolucent filling defects of the renal pelvis: classification and report of unusual cases","volume":"114","author":"Malek","year":"1975","journal-title":"J Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-5347(17)54881-8","article-title":"Management of high grade transitional cell cancer of the upper urinary tract","volume":"125","author":"Murphy","year":"1981","journal-title":"J Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000332528","article-title":"Endoscopic brush cytology of the upper urinary tract. Evaluation of its efficacy and potential limitations in diagnosis","volume":"41","author":"Dodd","year":"1997","journal-title":"Acta Cytol"},{"key":"10.1016\/j.soncn.2012.05.004_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.urology.2011.02.038","article-title":"Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management","volume":"78","author":"Smith","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.soncn.2012.05.004_bib17","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta1, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.urology.2005.10.022","article-title":"Laparoscopic nephroureterectomy for transitional cell carcinoma of renal pelvis and ureter: Nagoya experience","volume":"67","author":"Hattori","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.soncn.2012.05.004_bib19","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.eururo.2009.12.032","article-title":"Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma","volume":"57","author":"Li","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib20","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.juro.2009.12.018","article-title":"Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter","volume":"183","author":"Jeldres","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib21","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib23","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance Bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1442-2042.1996.tb00490.x","article-title":"Local toxicity patterns associated with intravesical Bacillus Calmette-Gu\u00e9rin: a Southwest Oncology Group Study","volume":"3","author":"Berry","year":"1996","journal-title":"Int J Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib25","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical Mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.soncn.2012.05.004_bib26","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0022-5347(01)67427-5","article-title":"Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder","volume":"153","author":"Lamm","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0094-0143(21)00419-5","article-title":"Complications of intravesical chemotherapy","volume":"19","author":"Thrasher","year":"1992","journal-title":"Urol Clin North Am"},{"issue":"2 Pt 1","key":"10.1016\/j.soncn.2012.05.004_bib28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0022-5347(17)35473-3","article-title":"Technique of mitomycin C\u00a0instillation in the treatment of upper urinary tract urothelial tumors","volume":"150","author":"Eastham","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib29","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0094-0143(05)70122-1","article-title":"Primary percutaneous approach to upper urinary tract transitional cell carcinoma","volume":"27","author":"Jabbour","year":"2000","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.soncn.2012.05.004_bib30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0959-8049(01)00393-8","article-title":"Current perspectives in muscle-invasive bladder cancer","volume":"38","author":"Sternberg","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.soncn.2012.05.004_bib31","series-title":"Textbook of bladder cancer","first-page":"657","article-title":"Neo-adjuvant chemotherapy in the treatment of muscle invasive bladder cancer","author":"Sternberg","year":"2006"},{"key":"10.1016\/j.soncn.2012.05.004_bib32","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1200\/JCO.1985.3.11.1463","article-title":"Cisplatin, methotrexate, and vinblastine: an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study","volume":"3","author":"Harker","year":"1985","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.soncn.2012.05.004_bib33","first-page":"98","article-title":"The role of cisplatin-based chemotherapy in advanced urothelial tract cancer","volume":"16","author":"Yagoda","year":"1989","journal-title":"Semin Oncol"},{"key":"10.1016\/j.soncn.2012.05.004_bib34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/bjc.1998.629","volume":"78","author":"Mead","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.soncn.2012.05.004_bib35","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.1997.15.12.3441","article-title":"Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer","volume":"15","author":"Moore","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2012.05.004_bib36","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1200\/JCO.2000.18.9.1921","article-title":"Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer","volume":"18","author":"Kaufman","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2012.05.004_bib37","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2012.05.004_bib38","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/oxfordjournals.annonc.a058668","article-title":"Second-line MVAC therapy in patients previously treated with the MVAC regimen for metastatic urothelial cancer","volume":"4","author":"Kattan","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soncn.2012.05.004_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1040-8428(02)00120-8","article-title":"Pharmacology of antineoplastic agents in older cancer patients","volume":"46","author":"Lichtman","year":"2003","journal-title":"Crit Rev Oncol Haematol"},{"key":"10.1016\/j.soncn.2012.05.004_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11136-005-0580-5","article-title":"Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment","volume":"15","author":"Osoba","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1016\/j.soncn.2012.05.004_bib41","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/bjc.1997.507","article-title":"Patient perceptions of the side-effects of chemotherapy: the influence of 5-HT3 antagonists","volume":"76","author":"de Boer-Dennert","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.soncn.2012.05.004_bib42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s003450050135","article-title":"When the bladder is gone: quality of life following different types of urinary diversion","volume":"17","author":"Mansson","year":"1999","journal-title":"World J Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1464-410X.1998.00763.x","article-title":"Can preoperative psychological defensive strategies and mood in bladder cancer patients and type of lower urinary tract reconstruction predict postcystectiomy psychological adjustment?","volume":"82","author":"Mansoon","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.soncn.2012.05.004_bib44","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0193945902250417","article-title":"The lived experience of having a neobladder","volume":"25","author":"Beitz","year":"2003","journal-title":"Western J Nurs Res"},{"key":"10.1016\/j.soncn.2012.05.004_bib45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1523-5394.2000.81005.x","article-title":"The sexual rehabilitation of persons with cancer","volume":"8","author":"Silver","year":"2000","journal-title":"Cancer Pract"},{"key":"10.1016\/j.soncn.2012.05.004_bib46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1464-410X.2008.08333.x","article-title":"Sexual function of patients under surveillance for bladder cancer","volume":"104","author":"van der Aa","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.soncn.2012.05.004_bib47","unstructured":"Urostomy and Continent Urinary Diversion. National Institute of Diabetes and Digestive and Kidney Diseases. Available at: http:\/\/kidney.niddk.nih.gov\/kudiseases\/pubs\/urostomy\/#urostomy. (accessed December 17, 2011)."}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208112000319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208112000319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:55:42Z","timestamp":1760072142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208112000319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0749208112000319"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2012.05.004","relation":{},"ISSN":["0749-2081"],"issn-type":[{"type":"print","value":"0749-2081"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urothelial Cancers: Ureter, Renal Pelvis, and Bladder","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2012.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}